{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-23-000145","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.481562+00:00","generated_at":"2026-06-11T12:27:35.323753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GRI Bio reports Q2 net loss of $8.9M, cash $4.8M, Phase 2a IPF study on track for H2 2023","bullets":["Net loss of $8.9M for six months ended June 30, 2023, primarily from increased R&D and G&A expenses.","Cash and equivalents $4.8M at June 30, 2023; merger with Vallon Pharmaceuticals closed.","R&D expenses Q2 2023: $0.9M (up from $0.1M); G&A $5.1M (up from $0.1M) due to merger costs.","Phase 2a biomarker study for GRI-0621 in IPF on track to launch in H2 2023.","IND-enabling studies for GRI-0803 in SLE ongoing; IND filing expected in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-23-000145","json":"https://secwatch.observer/filing/0001824293-23-000145.json","markdown":"https://secwatch.observer/filing/0001824293-23-000145.md","text":"https://secwatch.observer/filing/0001824293-23-000145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000145/0001824293-23-000145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000145/val-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:27:35.323753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20330a01cf7f115050423946deff727304aaed7c","claim":"GRI Bio, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2023, and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000145/0001824293-23-000145-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}